You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 22, 2018

Clearing the Air on Cannabis Patents

Bangkok Post

The patent system has become an unlikely hot topic in Thailand in light of reports that some overseas pharmaceutical companies have applied for Thai patents for cannabis. The revelations have added more fuel to the ongoing debate about the utility of cannabis, a Thai local plant. The reports have led many to criticize the patent system, questioning whether patent rights may obstruct Thai researchers’ studies on cannabis. It is important not to oversimplify this issue. Such dialogue is extremely important and must be encouraged, but as a patent attorney I find the broader context of the patent system very enlightening in understanding the arguments on both sides.

The most important context of course is the reasoning behind the patent system in the first place. An internationally accepted rationale for patent law is that a patent grants security to an inventor who, through his or her intellect and labor, has conceived an invention that benefits the society. Granting that inventor patent rights prevents others from exploiting the fruit of that inventor’s labor without consent. Simply put, patents prevent anyone from stealing an inventor’s idea. In exchange, the inventor has a duty to make the details (or the “secret trick”) of his or her invention available to the public through the process of patent application. Importantly, a patent is in force for no more than 20 years, after which the knowledge in that patent will become public information for anyone’s free use.

With that in mind, we can begin to look at the specific context of cannabis-based patents.

 

The patent system has become an unlikely hot topic in Thailand in light of reports that some overseas pharmaceutical companies have applied for Thai patents for cannabis. The revelations have added more fuel to the ongoing debate about the utility of cannabis, a Thai local plant. The reports have led many to criticize the patent system, questioning whether patent rights may obstruct Thai researchers’ studies on cannabis. It is important not to oversimplify this issue. Such dialogue is extremely important and must be encouraged, but as a patent attorney I find the broader context of the patent system very enlightening in understanding the arguments on both sides.

The most important context of course is the reasoning behind the patent system in the first place. An internationally accepted rationale for patent law is that a patent grants security to an inventor who, through his or her intellect and labor, has conceived an invention that benefits the society. Granting that inventor patent rights prevents others from exploiting the fruit of that inventor’s labor without consent. Simply put, patents prevent anyone from stealing an inventor’s idea. In exchange, the inventor has a duty to make the details (or the “secret trick”) of his or her invention available to the public through the process of patent application. Importantly, a patent is in force for no more than 20 years, after which the knowledge in that patent will become public information for anyone’s free use.

With that in mind, we can begin to look at the specific context of cannabis-based patents.

Current State of Cannabis Patents in Thailand

A preliminary investigation into the Department of Intellectual Property (DIP) database shows that 91 patent applications have been filed in Thailand relating to the group of chemicals found in cannabis. This search excludes any incidental uses such as traditional medicines and textile industry applications. Among these, only one application has been registered as a Thai patent, and that patent was later revoked. Of the remaining 90 applications, 51 were abandoned without registration. The remaining 39 have been published and are pending substantial examination by the DIP.

It is important to clarify that a patent application is not the same as patent registration. Rights do not exist until an application is registered, and before registration the applicant has no right to sue anyone. Therefore, no one, Thai or foreign, is currently able to sue anyone for infringing a cannabis extract patent in Thailand.

Natural Substances

One hotly debated point is whether or not people should be able to patent “natural substances.” This is an odd argument from a patent attorney’s point of view, because the law already addresses it. Section 9 (1) of the Thai Patent Act B.E. 2522 (1979) expressly prevents “animals, plants or extracts from animals or plants” from being patented. The next logical step is to dig deeper into what that actually means.

The DIP’s Patent Examination Guideline B.E. 2555 (2012), section 1, part 1, page 28, explains that unpatentable “animals, plants or extracts from animals or plants” includes “higher animals and higher plants that are available in nature” and “extracts from animals or plants that have not undergone any man-made substantial processing” (emphasis added). The underlying reason is that a protectable invention must owe its existence to human’s intelligence. The existence of plants, animals, or other things that exist in nature may not be claimed by a human. In cannabis’ case, this law means that the cannabis plant, including its stem, flower, leaf, and crude extracts are not patentable. 

On the other hand, if a human brings a natural thing to be processed by technical means, and thereby causes results and benefits that are not found in the natural state of that thing, then that processed natural thing may be patented. For example, suppose that a certain plant contains Substance A which, in its natural state, does not exhibit any therapeutic effects. Suppose that a researcher later found a way to transform Substance A, or make a pharmaceutical formula containing Substance A, which enables Substance A to perform as an active ingredient for effective treatment of hypertension. The method for transforming that substance, or the pharmaceutical formula, is an invention which may be lawfully patented.

Section 9 (1) must be interpreted with care, and in the proper context of the rationale for patent law, to avoid it leading to slippery slope arguments that negatively affect the patent system. It is true that all human inventions can be traced back to products of nature. For example, many polymers are derived from crude oil, which is found in nature. However, a new petroleum-based polymer that is stronger than steel should be patentable, despite being developed from a product of nature. If Section 9 (1) is interpreted to mean that anything related to nature in any way cannot be patented, then nothing would be patentable.

Preventing the Obstruction of Research

Another hotly debated issue surrounding cannabis patents is a concern that Thai patent registration (which has yet to occur, as noted above) may obstruct medical cannabis research by Thai researchers. This is a rather unlikely scenario for two extremely important reasons.

Firstly, patent protection has a limited scope. Using the Substance A example above, suppose that a patent has been issued for the use of Substance A as a treatment for hypertension (and that the patent has passed all other provisions of the Patent Act). That patent will only cover the use of Substance A for the reasons, and by the means, specified in the patent. The patentee has no right to prevent others from using Substance A for other purposes, for treating other illnesses, or for treating hypertension by a means that is substantially different from what is specified in the patent. In addition, since the patent claims for the “use,” not for Substance A itself (which cannot be patented, as noted above), the patentee is not entitled to prevent others from using or handling Substance A in any other way.

Secondly, research and study are not patent infringement. Section 36, paragraph 2, subsection 1 of the Patent Act provides that “any act for the purpose of study, research, experimentation or analysis” does not infringe upon any patent. This means any study or research that does not compete with the patentee’s business, such as a research conducted by a professor in a medical school, will not expose the researcher to any liability.

The Usefulness of Patents

Finally, in considering these matters in the broader context, it is important to be aware of the general usefulness of the patent system in a broader sense. The patenting system is important for the modern economy. It incentivizes research and development activities, and it allows for knowledge transfer for the public benefit. Patent applications must disclose clear and detailed information about the invention that they relate to, making the complete details of an invention publicly available, from which new ideas and further developments will arise. Researchers are free to study the patents and then seek a technical improvement, which may be patentable in its own right. In addition, when the patent has expired (no longer than 20 years), the once-patented invention will become public knowledge available for anyone’s free use.

The case of cannabis patents is a great opportunity for the Thai public to converse, debate, and consider the benefits and shortcomings of the current patent law system, and hopefully to provide critiques for the betterment of our patent law. However, it is important for any such critique to have a good understanding of the facts on both sides of the argument, before a thorough analysis can take place.

RELATED INSIGHTS​ 

June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
June 16, 2026
Since the implementation of the Trademark Law 2019 on April 1, 2023, Myanmar has operated under a modern first-to-file trademark system that brings its registration framework closer to international practice. As the new regime continues to develop in practice, applicants are increasingly required to navigate formal examination requirements, substantive objections, and procedural deadlines with greater precision. This article provides a high-level review of the trademark examination process in Myanmar, focusing on the principal stages from initial review to approval, the types of objections commonly raised by the Intellectual Property Department (IPD), and the key considerations for responding effectively. A clear understanding of these issues is essential for applicants seeking to secure registration efficiently and to mitigate avoidable delays or refusals. Examination Process: Key Stages Trademark applications filed with the IPD undergo two stages of review. Formality Examination The IPD first verifies compliance with procedural requirements, including: Correct Nice Classification Clear mark representation Accurate applicant details Clearly defined goods or services Representative details, if the application is filed by a representative Other formality requirements cover translation and transliteration of any non-English or non-Myanmar elements in the mark, color claim details, applicable disclaimers, and payment of official fees. Deficiencies result in an office action requiring correction within 30 days, which may be extended upon request. Registrability Examination The IPD also assesses registrability. A mark may be refused if it: Lacks distinctiveness Is descriptive or generic Misleads the public or violates public order/morality Contains prohibited state symbols Only compliant applications proceed to publication. Responding to Office Actions Applicants must respond within 30 days of notification from the IPD. Depending on the nature of the objection, strategies may include submitting legal arguments for distinctiveness, providing evidence of acquired distinctiveness, filing appropriate disclaimers, clarifying descriptions such as color claims, or amending the listed goods
June 15, 2026
The surge in AI development has led to a desperate demand for large, high-quality training data. However, real-world data can be expensive to collect, difficult to access, and often subject to strict privacy and regulatory constraints. Synthetic data, which consists of artificially generated records that replicate the statistical properties of real-world data without reproducing specific individuals’ information, provides an appealing solution by generating artificial datasets at scale without relying on identifiable personal information. It combines speed, cost efficiency, and regulatory compliance, making it a sensible alternative for organizations seeking to reduce risks while maintaining data utility. When properly anonymized, synthetic datasets may fall outside the scope of laws such as the EU’s General Data Protection Regulation (GDPR) or Thailand’s Personal Data Protection Act (PDPA), reducing compliance burdens while still supporting high-quality model training. However, relying on synthetic data without rigorous legal due diligence could be a strategic mistake. It replaces one set of known risks (scraping, direct privacy liability) with a new set of complex liabilities. The narrative that synthetic data is a “silver bullet” for privacy and IP compliance is dangerous and could be misleading. While synthetic data addresses data scarcity, it also introduces new legal uncertainties. Legal counsel should anticipate downstream risks arising from compromised data sources. Models trained on unlawfully obtained data may need to be decommissioned, even if their outputs appear lawful. What is synthetic data? Synthetic data refers to artificially generated information created using AI techniques such as deep learning and generative models. Instead of copying real records, it reproduces the statistical patterns and relationships found in the original dataset. Synthetic data generally falls into three categories: Fully synthetic data – Entirely new data points generated from learned patterns. The model studies the structure of the original data and produces records that resemble real-world
June 10, 2026
In March 2026, the Intellectual Property Office of Vietnam (IP Office) issued a decision refusing a trademark application after considering an opposition based primarily on copyright grounds. The outcome is noteworthy because the foreign brand owner had neither trademark registrations nor applications in Vietnam at the time the opposition was filed, and the IP Office has historically applied a stringent approach to oppositions relying on copyright. The Opposition Maurten is a well-known Swedish sports nutrition brand recognized globally for its innovative hydrogel technology, which is designed to help endurance athletes fuel more effectively without gastrointestinal discomfort. The brand’s distinctive logo is characterized by clean lines and a bold black-and-white color scheme, and has long been associated with the company’s performance products. The brand’s logo is displayed above. An identical mark was filed for registration by a Vietnamese trademark squatter. In 2023, a Vietnamese individual filed an application for registration of an identical mark (Application No. 4-2023-38668), a practice commonly observed in Vietnam as trademark squatting. The brand owner engaged Tilleke & Gibbins to assist with strategy and filing an opposition to the mark. At the time, Maurten had no trademark rights or meaningful use in Vietnam, and global marketing data showed only modest figures without any local presence. Thus, to convince the IP Office to refuse the squatter’s application, instead of relying on trademark rights or use evidence, the opposition strategy centered on the copyright protection of the logo itself, as copyright arises automatically in Vietnam upon creation of the work and does not require registration. (It is worth noting, however, that the IP Office has traditionally been cautious in accepting copyright as a basis for refusing trademark applications.) On September 24, 2024, an opposition was filed on three main grounds: confusing similarity, copyright infringement of the artistic work,